Orchard Therapeutics to present clinical data for OTL-101 & OTL-102
Category: #health  By Saipriya Iyer  Date: 2019-02-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Orchard Therapeutics to present clinical data for OTL-101 & OTL-102

Biopharma major Orchard Therapeutics has reportedly made it to the front page for having announced details of oral and poster presentations for new clinical data. As per sources familiar with the knowledge of the matter, the prominent commercial-stage biopharmaceutical firm’s new clinical data for OTL-101 and OTL-102 will be presented at the TCT (Transplantation and Cellular Therapy) Meetings of the CIBMTR (Center for International Blood and Marrow Transplant Research) and the ASBMT (American Society of Blood and Marrow Transplantation).

The presentations at both the ASBMT and the CIBMTR will be held between February 20 to February 24, 2019, at Houston, Texas.

According to an official press release by Orchard Therapeutics, Donald B. Kohn, M.D., Professor, Microbiology, Immunology & Molecular Genetics, University of California, LA, will be presenting clinical data from a current registrational clinical trial of OTL-101. The latter incidentally, is used for the treatment of ADA-SCID (adenosine deaminase severe combined immunodeficiency).

Reliable sources with the knowledge of the matter affirm that Dr. Kohn will also be responsible for presenting a detailed clinical proof-of-concept data for OTL-102, that is used for treating X-CGD (X-linked chronic granulomatous disease) – highlighted at the time of the Presidential Symposium, at the 2018 American Society of Hematology Annual Meeting and Exposition held in December.

As per credible reports, the oral presentation for OTL-101 and OTL-102 will focus on gene therapy for ADA-SCID and Lentiviral Gene Therapy for X-CGD (X-linked Chronic Granulomatous Disease) to be held at the George R. Brown Convention Center and Hilton Americas Houston respectively. The poster presentation for OTL-101, on the other hand, will revolve around autologous Ex Vivo Lentiviral Gene Therapy for treating ADA-SCID (Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency), also to be held at the George R. Brown Convention Center.

A completely integrated, commercial-stage biopharma magnate, Orchard Therapeutics is committed to transforming the lives of patients afflicted with life-threatening rare diseases through via highly innovative gene therapies.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471
Compass Therapeutics announces first-in-human Phase 1 trial of CTX-471
By Saipriya Iyer

CTX-471 has shown promising preclinical data, which include total eradication of established tumors in syngeneic mouse models.

Compass Therapeutics, a clinical-stag...

Amazon.in bets big on grocery category, expands Pantry to 110 cities
Amazon.in bets big on grocery category, expands Pantry to 110 cities
By Saipriya Iyer

Amazon Pantry expanding its footprint in smaller cities of India. The service was available over 40 cities in November 2018.

E-commerce giant Amazon.in has recently...

Medtronic unveils results from first-in-human study for EV ICD systems
Medtronic unveils results from first-in-human study for EV ICD systems
By Saipriya Iyer

Medtronic plc has reportedly unveiled the results from a test study of its investigational extravascular ICD system, where a lead is positioned outside of the heart and veins to provide anti-tachycardia pacing therapy ...